Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2019-04-14 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 7 pages 711.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 March 2019' and is described as a quarterly cash flow report for the quarter ended 31 March 2019. It contains detailed financial data including consolidated statements of cash flows, cash balances, payments to directors, financing facilities, and estimated cash outflows for the next quarter. The document references compliance with Listing Rule 4.7B and includes a compliance statement signed by the company secretary. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a financial report for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a full quarterly report with financial statements and analysis. Q3 2019
2019-04-14 English
CEO presentation to Phar East conference, Singapore 18 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Living Cell Technologies (LCT), describing its business, product pipeline, clinical trial data, regulatory strategy, and investment/licensing opportunities. It includes forward-looking statements, clinical trial results, product development timelines, and management information. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal regulatory filing, annual report, or earnings release. There is no indication that this is a transcript, audit report, or legal proceeding update. The document length is substantial (15,000 characters), and it contains detailed business and clinical information, consistent with an Investor Presentation (IP).
2019-03-07 English
Living Insights Newsletter February 2019 2 pages 470.1KB
Investor Presentation Classification · 85% confidence The document is titled 'Living Insights' and is described as an occasional newsletter providing updates on the Australasian biotechnology company Living Cell Technologies (LCT). It contains detailed updates on clinical trials, pipeline projects, regulatory interactions, financial status (net assets and cash flow), and upcoming events. The document includes financial data such as net assets and cash equivalents, and discusses operational cash flow and funding projections. However, it is not a formal financial report like an Annual Report (10-K) or Interim Report (IR). It is more of an investor update newsletter with scientific and business progress information. It does not fit the categories of earnings release, regulatory filing, or management report. It is not a presentation or call transcript. Given the nature of the document as a company newsletter providing updates on clinical trials, financial status, and strategic direction, it best fits the category of Investor Presentation (IP), which includes detailed presentations for investors focusing on financials, strategy, and market position. The document is longer than 5,000 characters and contains substantive information rather than just an announcement or link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the most appropriate classification is Investor Presentation (IP).
2019-02-28 English
Half Yearly Report and Accounts 22 pages 724.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Half yearly report ended 31 December 2018" and contains detailed financial information including consolidated operating loss, net assets, cash and cash equivalents, and a directors' report. It also includes financial statements such as the statement of profit or loss, statement of financial position, and notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial data and analysis for a six-month period clearly identifies this as an Interim / Quarterly Report. The document is not merely an announcement of the report but contains substantive financial data and management discussion. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2019
2019-02-18 English
Appendix 4C - quarterly 7 pages 719.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2018' and is described as a quarterly cash flow report for the quarter ended 31 December 2018. It contains detailed financial data including consolidated statements of cash flows, cash balances, payments to directors, and estimated cash outflows for the next quarter. The document references compliance with Listing Rule 4.7B and includes a compliance statement signed by the company secretary. The content is substantive financial data for a period shorter than a full fiscal year (quarterly), consistent with an Interim / Quarterly Report. It is not merely an announcement or a certification, but contains actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2019
2019-01-29 English
NTCELL Phase I IIa Parkinson's trial update 4 pages 457.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited providing an update on the Phase I/IIa clinical trial of their product NTCELL for Parkinson's disease. It discusses patient data, safety, and some efficacy results four years after implantation. The content is focused on clinical trial progress and results rather than financial performance or regulatory filings. There is no indication that this is a full financial report, audit report, or earnings release. It is not a presentation, call transcript, or management report. The document is a clinical trial update announcement, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into any other specific financial or corporate filing category.
2019-01-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.